Answers are grounded in this paper and cite their sources.
Analysis highlights China's leadership in clinical trials, indicating potential geopolitical challenges ahead.
After investing decades and billions of yuan in becoming a scientific superpower, China is well placed to benefit from the plight of the US medical research sector. But geopolitical ructions and local idiosyncrasies could complicate this, writes Flynn Murphy
No takes yet. Share an insight, caveat, or question.
F. A. Murphy (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: